JMP Securities started coverage on shares of Gamida Cell (NASDAQ:GMDA) in a research report report published on Friday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $16.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the stock. ValuEngine raised shares of Gamida Cell from a hold rating to a buy rating in a research report on Thursday, August 1st. Oppenheimer set a $18.00 price objective on shares of Gamida Cell and gave the company a buy rating in a research report on Wednesday, August 7th. Finally, Zacks Investment Research raised shares of Gamida Cell from a hold rating to a buy rating and set a $4.00 price objective for the company in a research report on Monday, August 12th. Eight research analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and an average price target of $16.43.

GMDA opened at $4.70 on Friday. The company has a 50-day moving average of $3.74 and a 200-day moving average of $6.85. Gamida Cell has a 1-year low of $2.93 and a 1-year high of $15.41. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.47 and a quick ratio of 4.47.

Gamida Cell (NASDAQ:GMDA) last released its earnings results on Tuesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.32). On average, sell-side analysts anticipate that Gamida Cell will post -1.16 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the stock. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Gamida Cell during the 1st quarter valued at about $53,000. Royal Bank of Canada bought a new stake in shares of Gamida Cell during the 2nd quarter valued at about $71,000. Bank Hapoalim BM bought a new stake in shares of Gamida Cell during the 2nd quarter valued at about $195,000. EcoR1 Capital LLC bought a new stake in shares of Gamida Cell during the 2nd quarter valued at about $265,000. Finally, Noked Capital LTD bought a new position in Gamida Cell in the 2nd quarter worth about $1,035,000. 25.86% of the stock is owned by institutional investors and hedge funds.

Gamida Cell Company Profile

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

See Also: P/E Growth (PEG)

Analyst Recommendations for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.